Komori
Sanno (3441) · FactRestated

Continuing Research and Development Activities

First written in FY2016-Q3. 30 of 34 entries say "Restated". Latest entry: FY2026-H1.

34entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q3 – FY2026-H12016: 320162017: 420172018: 320182019: 420192020: 320202021: 420212022: 320222023: 420232024: 320242025: 220252026: 1
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 190 companies write about · 0 as a headwind · 180 as a tailwind

99 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 190 companies compared. The sentences above are computed from all 190.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「The Group's total research and development expenditure during the interim consolidated fiscal period was ¥18 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated fiscal period.」

    The company recognized ¥18 million in R&D expenses and continued to state that there had been no material change in its research and development activities.
  2. FY2025Decrease in R&D expensesAnnual report

    「¥38.431 million was spent on research and development during the consolidated fiscal year.」

    Research and development activities continued, but R&D expenses decreased from ¥58.250 million in the previous consolidated fiscal year to ¥38.431 million.
  3. FY2025-H1Decrease in R&D expensesAnnual report

    「The Group's total research and development expenditure during the interim consolidated fiscal period was ¥18 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated fiscal period.」

    The Company stated that there were no material changes in the status of its research and development activities, while disclosing research and development expenditure of ¥18 million for the interim consolidated fiscal period. This was down from ¥25 million in the previous interim consolidated fiscal period.
  4. FY2024Decrease in R&D expensesAnnual report

    「The Company spent ¥58.250 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥58.250 million. This was down from ¥79.176 million in the previous consolidated fiscal year.
  5. FY2024-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥45 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥45 million and continued to explain that there were no material changes in the status of its research and development activities.
  6. FY2024-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥25 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥25 million and continued to explain that there were no material changes in the status of its research and development activities.
  7. FY2024-Q1RestatedAnnual report

    「The Group's total research and development expenditure for the first quarter was ¥10 million. There were no material changes in the status of our Group's research and development activities during the first quarter.」

    The Company recorded research and development expenditure of ¥10 million and continued to explain that there were no material changes in the status of its research and development activities.
  8. FY2023RestatedAnnual report

    「The Company spent ¥79.176 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥79.176 million. The development of hydrogen separation membranes and other items is tracked in t13.
  9. FY2023-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥56 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥56 million and continued to explain that there were no material changes in the status of its research and development activities.
  10. FY2023-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥30 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥30 million and continued to explain that there were no material changes in the status of its research and development activities.
  11. FY2023-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥15 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥15 million and continued to explain that there were no material changes in the status of its research and development activities.
  12. FY2022-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥40 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥40 million and continued to explain that there were no material changes in the status of its research and development activities.
  13. FY2022-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥28 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥28 million and continued to explain that there were no material changes in the status of its research and development activities.
  14. FY2022-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥14 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed quarterly research and development expenditure of ¥14 million, along with the absence of material changes in the status of those activities.
  15. FY2021RestatedAnnual report

    「The Company spent ¥74.381 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥74.381 million.
  16. FY2021-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥50 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥50 million and continued to explain that there were no material changes in the status of its research and development activities.
  17. FY2021-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥19 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥19 million and maintained its explanation that there were no material changes in the status of its research and development activities.
  18. FY2020RestatedAnnual report

    「The Company spent ¥66.235 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥66.235 million.
  19. FY2020-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥49 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company maintained its explanation that there were no material changes in its research and development activities and disclosed research and development expenditure of ¥49 million for the cumulative period.
  20. FY2020-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥32 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥32 million and maintained its explanation that there were no material changes in the status of its research and development activities.
  21. FY2020-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥15 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company maintained its explanation that there were no material changes in its research and development activities and disclosed quarterly research and development expenditure of ¥15 million.
  22. FY2019RestatedAnnual report

    「The Company spent ¥86.019 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥86.019 million.
  23. FY2019-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥63 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥63 million and maintained its explanation that there were no material changes in the status of its research and development activities.
  24. FY2019-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥43 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥43 million and maintained its explanation that there were no material changes in the status of its research and development activities.
  25. FY2019-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥22 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company maintained its explanation that there were no material changes in its research and development activities and disclosed quarterly research and development expenditure of ¥22 million.
  26. FY2018-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥68 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥68 million and maintained its explanation that there were no material changes in the status of its research and development activities.
  27. FY2018-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥47 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company maintained its explanation that there were no material changes in its research and development activities and disclosed quarterly research and development expenditure of ¥47 million.
  28. FY2018-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥18 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company recorded research and development expenditure of ¥18 million and disclosed that there were no material changes in the status of its research and development activities.
  29. FY2017RestatedAnnual report

    「The Company spent ¥65.966 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and recorded full-year research and development expenditure of ¥65.966 million.
  30. FY2017-Q3RestatedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥48 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed quarterly research and development expenditure of ¥48 million, along with the absence of material changes in the status of those activities.
  31. FY2017-Q2RestatedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥30 million. There were no material changes in the status of the Group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed quarterly research and development expenditure of ¥30 million, along with the absence of material changes in the status of those activities.
  32. FY2017-Q1RestatedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥12 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed quarterly research and development expenditure of ¥12 million, along with the absence of material changes in the status of those activities.
  33. FY2016RestatedAnnual report

    「The Company spent ¥47.372 million on research and development during the current consolidated fiscal year.」

    The Company continued its research and development activities and disclosed full-year research and development expenditure of ¥47.372 million.
  34. FY2016-Q3First statedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥34 million. There were no material changes in the status of the Group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The Company disclosed research and development expenditure of ¥34 million and stated that there were no material changes in the status of its research and development activities.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sanno yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continuing Research and Development Activities | SANNO Co.,Ltd. (3441) | Komori